HSBC Holdings
RXRX icon

HSBC Holdings’s Recursion Pharmaceuticals RXRX Stock Holding History

HSBC Holdings’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$753K Sell
246,757
-571,559
-70% -$2.21M ﹤0.01% 2008
2025
Q4 		$3.37M Buy
818,316
+689,903
+537% +$3.42M ﹤0.01% 1362
2025
Q3 		$614K Buy
128,413
+111,840
+675% +$587K ﹤0.01% 2000
2025
Q2 		$85.9K Sell
16,573
-20,863
-56% -$102K ﹤0.01% 2873
2025
Q1 		$197K Buy
37,436
+1,097
+3% +$8K ﹤0.01% 2626
2024
Q4 		$249K Buy
36,339
+11,822
+48% +$79.5K ﹤0.01% 2598
2024
Q3 		$164K Sell
24,517
-3,455
-12% -$24.8K ﹤0.01% 2688
2024
Q2 		$206K Buy
27,972
+5,764
+26% +$50.3K ﹤0.01% 2534
2024
Q1 		$221K Buy
+22,208
New +$247K ﹤0.01% 2626
2023
Q3 		– Sell
-19,495
Closed -$148K – 2826
2023
Q2 		$148K Buy
19,495
+9,004
+86% +$63K ﹤0.01% 2384
2023
Q1 		$70.3K Buy
10,491
+290
+3% +$2.3K ﹤0.01% 2542
2022
Q4 		$76.3K Hold
10,201
– – ﹤0.01% 2939
2022
Q3 		$111K Sell
10,201
-2,870
-22% -$29.1K ﹤0.01% 2736
2022
Q2 		$105K Buy
+13,071
New +$87.5K ﹤0.01% 3029

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HSBC Holdings's RXRX Position: Q1 2026 in Review

HSBC Holdings reduced its Recursion Pharmaceuticals (RXRX) stake by 70% in Q1 2026, selling an estimated $2.21M and leaving 246,757 shares worth $753K. The position accounts for ﹤0.01% of the portfolio, ranked #2008.

HSBC Holdings first reported a position in RXRX in Q2 2022 and has held it in 14 quarters since. The position peaked at $3.37M in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • HSBC Holdings held 246,757 shares of Recursion Pharmaceuticals worth $753K as of Q1 2026.
  • HSBC Holdings sold 571,559 Recursion Pharmaceuticals shares in Q1 2026, an estimated $2.21M.
  • Recursion Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2008 holding.
  • HSBC Holdings first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
  • HSBC Holdings's Recursion Pharmaceuticals position peaked at $3.37M in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.